European enhanced surveillance of invasive pneumococcal disease in 2010: Data from 26 European countries in the post-heptavalent conjugate vaccine era

Adoración Navarro Torné*, Joana Gomes Dias, Chantal Quinten, Frantiska Hruba, Marta Cecilia Busana, Pier Luigi Lopalco, Andrew J.Amato Gauci, Lucia Pastore-Celentano, Martine Sabbe, Jan Verhaegen, Maria Koliou, Despo Pieridou-Bagkatzouni, Pavla Křižovà, Jana Kozakova, Jitka Motlova, Palle Valentiner-Branth, Lotte Lambertsen, Theano Georgakopoulou, Hilary Humphreys, Tanya MelilloPaul Caruana, Mirjam Knol, Hester de Merkel, Karin Elberse, Didrik Frimann, Anna Skoczynska, Waleria Hryniewicz, Alicja Kuch, Iwona Paradowska-Stankiewicz, Marina Pana, Marta Vitek, Veronika Učakar, Birgitta Henriques Normark, Tiia Lepp, Mary Slack, Pauline A. Waight

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)

Abstract

Streptococcus pneumoniae is a leading cause of severe infectious diseases worldwide. This paper presents the results from the first European invasive pneumococcal disease (IPD) enhanced surveillance where additional and valuable data were reported and analysed. Following its authorisation in Europe in 2001 for use in children aged between two months and five years, the heptavalent pneumococcal conjugate vaccine (PCV7) was progressively introduced in the European Union (EU)/European Economic Area (EEA) countries, albeit with different schemes and policies. In mid-2010 European countries started to switch to a higher valency vaccine (PCV10/PCV13), still without a significant impact by the time of this surveillance. Therefore, this surveillance provides an overview of baseline data from the transition period between the introduction of PCV7 and the implementation of PCV10/PCV13.In 2010, 26 EU/EEA countries reported 21 565 cases of IPD to The European Surveillance System (TESSy) applying the EU 2008 case definition. Serotype was determined in 9. 946/21. 565 (46.1%) cases. The most common serotypes were 19A, 1, 7F, 3, 14, 22F, 8, 4, 12F and 19F, accounting for 5. 949/9. 946 (59.8%) of the serotyped isolates. Data on antimicrobial susceptibility testing (AST) in the form of minimum inhibitory concentrations (MIC) were submitted for penicillin 5. 384/21. 565 (25.0%), erythromycin 4. 031/21. 565 (18.7%) and cefotaxime 5. 252/21. 565 (24.4%). Non-susceptibility to erythromycin was highest at 17.6% followed by penicillin at 8.9%.PCV7 serotype coverage among children <5 years in Europe, was 19.2%; for the same age group, the serotype coverage for PCV10 and PCV13 were 46.1% and 73.1%, respectively.In the era of pneumococcal conjugate vaccines, the monitoring of changing trends in antimicrobial resistance and serotype distribution are essential in assessing the impact of vaccines and antibiotic use control programmes across European countries.

Original languageEnglish
Pages (from-to)3644-3650
Number of pages7
JournalVaccine
Volume32
Issue number29
DOIs
Publication statusPublished - 17 Jun 2014

Keywords

  • Antimicrobial resistance
  • Europe
  • Invasive pneumococcal disease
  • Pneumococcal vaccines
  • Serotype
  • Surveillance

Fingerprint

Dive into the research topics of 'European enhanced surveillance of invasive pneumococcal disease in 2010: Data from 26 European countries in the post-heptavalent conjugate vaccine era'. Together they form a unique fingerprint.

Cite this